US Material Events SEC 8-K Filings — September 14, 2026

14-09-2026

Bally's Corporation announced new financing led by WhiteHawk Capital Partners to support the Bally's Bronx project, comprising $400 million in closing date term loans and $160 million in delayed draw term loans, totaling $560 million. The financing is expected to close in Q3 2026, subject to regulatory approval and customary conditions. Proceeds will fund pre-construction costs and general corporate purposes, providing additional liquidity and flexibility.

• · Financing expected to close in Q3 2026, subject to regulatory approval and customary closing conditions.
• · Bally's has rights to developable land in Las Vegas at the former Tropicana Las Vegas site.
• · Bally's has been awarded a license to build a full-scale casino and resort in The Bronx, New York, and an integrated destination resort in Chicago, Illinois.
• · Bally's is the first publicly traded gaming company to achieve MBE certification through NMSDC.
• · Bally's holds a majority interest in Bally's Intralot S.A., active in 39 jurisdictions worldwide.
• · Bally's casino operations include approximately 17,700 slot machines, 630 table games, and 3,950 hotel rooms.

14-09-2026

Trilogy Metals closed a US$35.6 million strategic equity investment from the U.S. Department of War, making the U.S. Government an approximately 10% shareholder and advancing domestic copper supply from Alaska's Ambler Mining District. The proceeds will be fully deployed to advance exploration and development of the Upper Kobuk Mineral Projects, with the DOW committing to help facilitate financing for the proposed 211-mile Ambler Road. However, South32's beneficial ownership in Trilogy was reduced from approximately 10.7% to 6.0% as part of the transaction, reflecting a dilution of its stake.

• · The DOW has a 10-year option to purchase 6,161,678 common shares of Trilogy from South32 at US$0.01 per share.
• · South32's beneficial ownership decreased from 18,595,311 shares (10.7%) to 10,379,741 shares (6.0%).
• · The Arctic Project received a Clean Water Act Section 404 permit application filing in April 2026 and was accepted as a FAST-41 Covered Project on May 15, 2026.
• · The UKMP land package spans approximately 190,929 hectares.
• · The proposed Ambler Road is 211 miles long and industrial-use-only.
• · The securities were sold in a private placement and are not registered under the Securities Act of 1933.

14-09-2026

Drugs Made In America Acquisition Corp. (DMAA), a SPAC, entered into an amended and restated definitive merger agreement with Power Analytics Global Corp (PAGC), a private AI and analytics company, dated September 8, 2026. The merger values PAGC at a Closing Valuation of US$2,850,000,000, with DMAA to domesticate as a Delaware corporation and PAGC surviving as a wholly-owned subsidiary. The agreement amends the original April 29, 2026 merger agreement, and the parties have abandoned a contingent amendment that would have added a second target with a combined equity value of US$3,000,000,000.

• · The merger is an affiliated business combination because PAGC and BV Advisory Partners, LLC (holding convertible notes and entitled to at least 40% of sponsor-level economics) are under common principal ownership.
• · The contingent amendment to add an additional target (APQC) with a combined equity value of US$3,000,000,000 has not become effective and becomes void if conditions are not satisfied by September 30, 2026; the parties do not intend to bring it into effect.
• · PAGC has entered into a Letter of Intent with APQC Inc and Santosh Kumar dated July 23, 2026, to acquire 100% of APQC, with the APQC Acquisition intended to be completed prior to Closing.
• · The Closing Valuation is subject to delivery of a Fairness Opinion, determinations by independent directors, and approval by DMAA's board.
• · The agreement includes a Debt-Free Condition requiring PAGC to be free of material indebtedness at Closing, other than Bridge Financing and ordinary trade payables.

14-09-2026

VisionWave Holdings entered into a letter agreement with YA II PN, Ltd. to facilitate the Second Closing under its Securities Purchase Agreement, issuing a $5,000,000 Convertible Debenture (VWAV-5) at par. The gross proceeds are irrevocably applied to repay principal under the February 2026 Note, reducing its balance from $7,469,178.42 to $2,469,178.42, with installment dates rescheduled to October, November, and December 2026. The February Warrant's exercise price was reduced from $9.00 to $1.50 per share, subject to Nasdaq Rule 5635 shareholder approval, and the company must call a shareholder meeting within 60 days to seek approval for share issuances above the cap.

• · First Installment Date under all Debentures deferred to January 30, 2027; no payments due before that date.
• · No Payment Premium, Redemption Premium, default interest, or other penalty payable due to the rescheduling.
• · February Warrant exercise price reduction is subject to Nasdaq Listing Rule 5635 cap; excess portion remains exercisable at $9.00 until shareholder approval is obtained.
• · Company must file a Form 8-K within 4 business days of the letter agreement date.
• · Company must use reasonable best efforts to maintain effectiveness of registration statement for resale of February Warrant shares.

14-09-2026

Clean Energy Technologies, Inc. (CETY) entered into a Securities Purchase Agreement with Walnut Capital, LLC on September 8, 2026, issuing a $166,500 promissory note (including $16,500 original issue discount) in a private placement exempt from SEC registration. The company has 12,166,106 common shares outstanding out of 133,333,333 authorized, and disclosed a $6,000 broker fee obligation to Carter, Terry and Company, Inc. No period-over-period financial comparisons were provided in this filing.

• · The note includes a $16,500 original issue discount, meaning net proceeds to the company are approximately $150,000.
• · The securities are unregistered and bear a restrictive legend; removal requires registration or a legal opinion.
• · The company represents no material adverse change since December 31, 2025, except as disclosed in SEC filings.
• · No litigation is pending or threatened against the company beyond what is in SEC filings.
• · The company has 133,333,333 authorized common shares and 12,166,106 outstanding as of the agreement date.

14-09-2026

On September 8, 2026, TransparentBusiness, Inc. (Unicoin Inc.) announced the resignation of Deniece Ky, Principal Accounting Officer and Senior Financial Director, effective September 17, 2026, due to personal reasons. The company will pay $42,755.89 for accrued but unused PTO. No replacement has been announced, and no other financial or operational metrics were disclosed.

14-09-2026

BioVie Inc. entered into a Sales Agreement with A.G.P./Alliance Global Partners on September 11, 2026, to sell up to $6,464,341 of its Class A common stock in at-the-market offerings. The company will pay a 3.0% commission on gross proceeds and intends to use the funds for general corporate purposes. The agreement provides flexibility but does not obligate the company to sell any shares.

• · The Registration Statement (File No. 333-296924) was filed on June 18, 2026 and declared effective on June 29, 2026.
• · The prospectus supplement was filed with the SEC on September 11, 2026.
• · The Sales Agreement may be terminated by either party, and the company may suspend offers at any time.
• · The offering will terminate upon the earlier of: (a) sale of all Placement Shares, (b) expiration of the Registration Statement on the third anniversary of its effective date, or (c) termination of the Agreement.

14-09-2026

Embrace Change Acquisition Corp. (EMCG) announced the termination of its merger agreement with Tianji Tire Global (Cayman) Limited, originally entered on January 26, 2025 and amended on October 16, 2025. Tianji delivered a termination notice on September 10, 2026, citing the failure to consummate the merger by the August 12, 2026 outside date. The termination was not due to any breach by EMCG, but the deal has been abandoned, leaving EMCG without a target business combination.

• · The Merger Agreement was originally signed on January 26, 2025 and amended on October 16, 2025.
• · The termination was effective as of September 10, 2026, per Section 11.1(d)(i) of the Merger Agreement.
• · The outside date for the merger was August 12, 2026.
• · The termination right was not available to a party if the failure to close was due to that party's breach; the filing does not indicate any breach by EMCG.

14-09-2026

American Tower Corporation completed a registered public offering of $1.6 billion in senior unsecured notes across three tranches: $500M of 5.300% notes due 2031, $500M of 5.560% notes due 2033, and $600M of 5.750% notes due 2036. Net proceeds of approximately $1.5799 billion will be used to repay $600M of 1.450% notes due 2026, reduce borrowings under its $6.0 billion revolving credit facility, and for general corporate purposes. The offering increases the company's debt and interest expense, but refinances lower-coupon debt with longer-dated maturities.

• · The notes were issued under a Base Indenture dated June 2, 2025, as supplemented by Supplemental Indenture No. 3 dated September 14, 2026.
• · Interest on the notes is payable semi-annually on March 15 and September 15, beginning March 15, 2027, computed on a 360-day year of twelve 30-day months.
• · The indenture limits the company's ability to merge, consolidate, or sell assets, and limits the company and its subsidiaries from incurring liens, with a maximum secured indebtedness of 3.5x Adjusted EBITDA.
• · The company may redeem the notes at any time, with a make-whole premium if redeemed before certain dates (August 15, 2031 for 2031 notes; July 15, 2033 for 2033 notes; June 15, 2036 for 2036 notes), and at par thereafter.
• · Upon a Change of Control and Ratings Decline, the company must offer to repurchase the notes at 101% of principal plus accrued interest.
• · Events of default include 30-day payment default on interest, payment default on principal, failure to comply with covenants for 90 days after notice, and certain bankruptcy/insolvency events.
• · If a bankruptcy event of default occurs, principal and accrued interest become immediately due without further action; for other defaults, the trustee or holders of at least 25% of principal may accelerate the notes.

14-09-2026

Ingles Markets, Inc. filed an 8-K on September 14, 2026, disclosing the adoption of Amended and Restated Bylaws effective September 8, 2026. The amendments primarily update provisions related to capital stock (including electronic issuance and transfer of shares), shareholder meetings (including remote communication), and record-keeping procedures. The filing also covers Items 5.02 (Director/Officer Departure/Election), 5.03 (Amendments to Articles of Incorporation or Bylaws), and 8.01 (Other Events), but no specific officer changes or financial metrics are detailed in the exhibit.

• · The Amended and Restated Bylaws were adopted effective September 8, 2026.
• · The bylaws permit the issuance of shares without physical certificates via electronic or other means, subject to applicable law.
• · Shareholders holding at least 10% of voting power may call special meetings.
• · The bylaws allow shareholder meetings to be held solely by remote communication at the Board's discretion.
• · Notice of shareholder meetings must be given 10 to 60 days in advance (20 days for mergers/consolidations).

14-09-2026

Glucotrack, Inc. held a Special Meeting on September 11, 2026, where stockholders approved two key proposals for Nasdaq compliance: the full issuance of shares under the ELOC Purchase Agreement with White Lion Capital, LLC, and the full issuance of shares upon conversion of Bridge Notes and exercise of Bridge Warrants. Both proposals passed with strong support (approximately 84.7% and 84.8% of votes cast in favor, respectively). However, the company also amended its Common Warrants to require stockholder approval before any exercise, reflecting ongoing dilution management and regulatory compliance efforts.

• · The Adjournment Proposal (Proposal 3) was not presented because sufficient votes were already cast to approve Proposals 1 and 2.
• · The Common Warrants Amendment (Exhibit 4.1) was entered into on September 14, 2026, to restrict exercise until stockholder approval is obtained.
• · The ELOC Purchase Agreement and Bridge Financing agreements were both dated July 14, 2026, with the Bridge Notes and Bridge Warrants issued on August 4, 2026.
• · The company's common stock is traded on Nasdaq under the symbol GCTK.

14-09-2026

Addentax Group Corp. entered into a private placement agreement with investor Chan Chun Hong on September 9, 2026, to issue 520,834 shares of common stock at $4.80 per share for aggregate gross proceeds of approximately $2.5 million. The proceeds will be used for general corporate purposes, including working capital and potential strategic investments. The offering is being conducted under Regulation S and is exempt from registration under the Securities Act.

• · The private placement is exempt from registration under Regulation S of the Securities Act.
• · The investor is not a 'U.S. person' as defined in Regulation S.
• · The shares will bear customary restrictive legends under the Securities Act.
• · The closing is subject to customary closing conditions.

14-09-2026

State Street Corporation announced two executive leadership appointments effective September 14, 2026. Mostapha Tahiri, formerly Enterprise Chief Operating Officer, has been appointed President of State Street Alpha and will continue as Chairman of Asia Pacific. Ann Fogarty, formerly Investment Services Chief Operating Officer, has been appointed Enterprise Chief Operating Officer, succeeding Mr. Tahiri, with a target incentive compensation award of $5,650,000.

• · Ann Fogarty, age 60, had served as State Street’s Executive Vice President and Chief Operating Officer of Investment Services since July 2025.
• · From March 2022 to July 2025, she served as Executive Vice President and Head of Global Delivery.
• · Ms. Fogarty joined State Street in March 2021 as Executive Vice President and Deputy Head of Global Delivery.
• · Prior to joining State Street, she served as Global Head of Operations for BNY Mellon from February 2018 to February 2021.
• · Ms. Fogarty also served as Global Head of Fund Accounting and Administration at BNY Mellon from March 2015 to February 2018.
• · She served as Head of Hedge Fund Administration at AIB Capital Markets from January 1995 to December 2002.

14-09-2026

PDS Biotechnology announced the initial closing of a PIPE financing led by Dr. Patrick Soon-Shiong's Nant Capital, raising gross proceeds of $11.3 million, with a potential additional $11 million at a milestone closing tied to a Phase 3 protocol submission. Dr. Soon-Shiong joined the board of directors, and the company granted NantWorks a one-year exclusive right to negotiate a license for PDS0101. The company plans to use proceeds to repay debt and fund clinical development, including advancing PDS0301 into late-stage trials, but faces risks including the milestone closing not being completed and reliance on additional financing.

• · Share Unit Purchase Price: $0.2825 per unit (one share + one-half warrant)
• · Pre-Funded Unit Purchase Price: $0.28217 per unit
• · 19.9% beneficial ownership limitation applies to securities purchased
• · PDS0301 showed promising interim Phase 2 data in MSS/pMMR metastatic colorectal cancer
• · PDS0101 is an investigational HPV-targeted immunotherapy
• · Dr. Soon-Shiong has over 100 peer-reviewed publications and over 500 patents
• · The PIPE was priced to satisfy Nasdaq Minimum Price requirement
• · Securities sold in the PIPE are unregistered and subject to a registration rights agreement

14-09-2026

Toyota Motor Credit Corporation (TMCC) renewed its Euro Medium Term Note (EMTN) Programme on September 11, 2026, for a one-year period, with an aggregate authorized principal amount of €60 billion shared among TMCC and its affiliates (Toyota Motor Finance (Netherlands) B.V., Toyota Credit Canada Inc., and Toyota Finance Australia Limited). The renewal also involved amended and restated agency agreements with The Bank of New York Mellon. This is a routine refinancing/administrative update with no immediate financial impact disclosed.

• · The EMTN Program was renewed for a period of one year.
• · Notes issued under the EMTN Program are unsecured and may be issued in bearer or registered form.
• · Notes issued under Regulation S are not registered under the Securities Act and may not be offered or sold to U.S. persons absent registration or exemption.
• · The Agency Agreement and Note Agency Agreement are dated September 11, 2026, and filed as Exhibits 4.1 and 4.2, respectively.

14-09-2026

Hain Celestial reported fiscal Q4 and FY2026 results with net sales declining 28% YoY to $263M in Q4 and 13% YoY to $1,353M for the full year, driven by divestitures and organic volume declines. However, the company significantly improved cash flow, with operating cash flow up ~250% YoY to $78M for the year and free cash flow turning positive at $58M. The company also announced a definitive agreement to sell its International business, aiming to become a more focused North American company, while noting the need to extend its December debt maturity.

• · Net secured leverage ratio at end of Q4 FY2026 was 4.5x as calculated under the credit agreement.
• · North America Q4 adjusted EBITDA margin improved 940 bps YoY to 14.4% of net sales.
• · International Q4 gross margin and adjusted gross margin both decreased 555 bps YoY to 16.6%.
• · Baby & Kids category organic net sales declined 11% in Q4 and 12% in FY2026.
• · Snacks category (now only International jellies) organic net sales declined 7% in both Q4 and FY2026.
• · Personal Care category net sales declined 19% in Q4 and 21% in FY2026 (held for sale).
• · Meal Prep organic net sales grew 3% in Q4 but were flat for FY2026.
• · Beverages organic net sales declined 2% in Q4 but grew 1% for FY2026.
• · Adjusted net loss per diluted share was $0.05 in Q4 FY2026 vs $0.02 in Q4 FY2025.
• · Adjusted net loss per diluted share was $0.17 in FY2026 vs adjusted EPS of $0.09 in FY2025.

14-09-2026

Rare Element Resources Ltd. appointed Josef Bilant as Chief Operating Officer, effective October 5, 2026. The appointment, alongside a new employment agreement detailing a US$330,000 base salary, a US$99,000 sign-on bonus, and performance-based compensation, strengthens the company's operational leadership. However, the filing solely announces an officer change and does not provide any financial results or performance metrics, so there is no data on growth or decline to report.

• · Josef Bilant, 41, holds an MBA from Temple University and a B.S. in Metallurgical Engineering from Montana Technological University.
• · No family relationships exist between Mr. Bilant and any director or executive officer of the registrant.
• · Sign-on bonus of $99,000 is subject to repayment if employment terminates voluntarily or for cause on or before October 5, 2028.
• · Long-term incentive awards may be determined by the Board, but amounts are not specified.
• · Non-compete covers rare earth activities globally and certain gold activities within a 5-mile radius of the Bear Lodge Project, unless terminated without cause.
• · The filing contains no financial results, period-over-period comparisons, or other quantitative business metrics.

14-09-2026

Flowserve Corp. announced the appointment of Brian Ezzell as Senior Vice President and Chief Financial Officer, effective October 1, 2026, succeeding Amy Schwetz who is leaving for another company. The company expects no changes to its full-year guidance.

• · Brian Ezzell joined Flowserve in October 2024 as Vice President, FP&A, Treasurer, and Investor Relations.
• · Prior to Flowserve, Ezzell spent four years as Vice President, Enterprise FP&A at Kimberly-Clark Corp., with finance responsibility for the $14 billion global supply chain.
• · Ezzell is a Certified Public Accountant and began his career at PricewaterhouseCoopers.
• · The company expects no changes to its full-year guidance following the CFO transition.

14-09-2026

NPK International Inc. announced the appointment of James 'JJ' Barton as Executive Vice President, Commercial Growth & Operations, effective September 22, 2026, succeeding Lori Briggs who departs effective September 14, 2026. The filing highlights Barton's extensive experience in strategic sales, operations, and growth execution, but provides no financial metrics or performance data for period-over-period comparison.

• · James Barton holds an MBA in Corporate Entrepreneurship from Syracuse University and a B.A. in Communication and Marketing from Louisiana State University.
• · Lori Briggs served NPK for 8 years before departing.
• · Barton most recently served as President of Clear Water Services, a wholly owned subsidiary of Tidal Vision.

14-09-2026

On September 11, 2026, Edward M. Weil, Jr. resigned from the board of directors of National Healthcare Properties, Inc., effective immediately. The resignation was not due to any disagreement with the company's operations, policies, or practices. The company filed this 8-K to disclose the departure.

• · Resignation effective September 11, 2026
• · No disagreement with company operations, policies, or practices

14-09-2026

Rimini Street, Inc. reinstated Steven Hershkowitz as Executive Vice President and Chief Revenue Officer effective September 14, 2026, just six days after his previously reported resignation on September 8, 2026. His previous annual base salary of $480,000 and annual incentive compensation opportunity of $320,000.16 (at 100% attainment) were reinstated, and CRO responsibilities previously transferred to COO Keith Costello were reassigned back to Hershkowitz. The filing does not disclose any financial metrics or performance data, so no period-over-period comparisons are available.

• · Hershkowitz originally joined Rimini Street as EVP and CRO in April 2024.
• · Prior to Rimini Street, Hershkowitz was CRO at Virtana Corporation from February 2022 to April 2024, where he led a transition from hardware-based perpetual license to a software, subscription and SaaS model.
• · From April 2010 to February 2022, Hershkowitz held multiple roles at HPE, most recently as VP and GM of the High Performance Compute and AI organization, and previously as VP and GM of HPE's North America Large Enterprise.
• · Hershkowitz is a U.S. Air Force veteran and studied Business Administration and Management at the University of Maryland.
• · No family relationships with any executive officer or director, and no transactions requiring disclosure under Item 404(a) of Regulation S-K.

14-09-2026

Cambium Networks Corp's subsidiary CNL filed for administration in the UK High Court on September 14, 2026. The company simultaneously cut 260 employees (53.6% of workforce) effective September 11 without severance, including SVP Products Vibhu Vivek. The administrators will attempt to sell assets and business lines, but the company expects the remaining CNL group entities to be wound up.

• · The subsidiary CNL filed for administration under the Insolvency Act 1986 and Insolvency (England and Wales) Rules 2016.
• · The filing was made in the High Court of Justice Business and Property Courts of England and Wales.
• · No severance payments were offered or made to the 260 terminated employees.
• · Costs associated with the restructuring could not be estimated at the time of filing.
• · The company's ordinary shares trade under the symbol CMBMF (N/A exchange).

14-09-2026

Graco Inc. appointed Richard B. Lewis, President and CEO of Donaldson Company, to its Board of Directors, effective December 3, 2026. Mr. Lewis will serve on the Audit Committee. The appointment reflects Graco's focus on adding senior operational and commercial leadership from a public manufacturing company, with no financial terms disclosed.

• · Richard B. Lewis has been CEO of Donaldson Company since March 2026.
• · Lewis previously served as Donaldson's Chief Operating Officer and President of its Mobile Solutions and Life Sciences businesses.
• · Lewis holds a bachelor's degree in industrial engineering from the University of Louisville and an MBA from Indiana University-Purdue University Indianapolis.
• · Lewis will join Graco's Audit Committee.

14-09-2026

Future Vision II Acquisition Corp. (FVNNR) entered into a $65,000 unsecured promissory note with HWei Super Speed Co. Ltd. to extend the deadline for its initial business combination by one month, from September 13, 2026 to October 13, 2026. The note is non-interest bearing and must be deposited into the trust account, with the principal due upon consummation of a business combination or at liquidation. The payee has the option to convert the principal into units at $10.00 per unit upon a business combination, but if no deal occurs and the SPAC liquidates, the note is forgiven, and the payee waives all claims against the trust account.

• · The note is unsecured and non-interest bearing.
• · Conversion option: up to $1.5M aggregate principal of extension loans can be converted into units at $10.00 per unit.
• · If no business combination occurs and the SPAC liquidates, the note is forgiven and the payee waives all rights to the trust account.
• · Note may not be assigned or transferred prior to business combination without Maker's written consent.
• · Events of default include failure to pay within 5 business days or voluntary bankruptcy.
• · Governing law: New York.

14-09-2026

Harvard Apparatus Regenerative Technology, Inc. (HRGN) raised $2,838,911 in a private placement on September 11, 2026, issuing 2,703,727 shares of common stock at $1.05 per share to accredited investors. The CEO, Jerry (Junli) He, participated by converting $717,911 of outstanding bridge notes into 683,725 shares at the same price, with the notes cancelled in full. The offering was conducted without registration under Section 4(a)(2) and Rule 506 of the Securities Act.

• · The private placement closed on September 11, 2026.
• · Shares were sold to accredited investors under Section 4(a)(2) and Rule 506 exemptions.
• · The bridge notes converted were issued on April 14, 2026, May 13, 2026, and July 16, 2026.
• · The Purchase Agreement includes customary representations, warranties, and covenants.
• · Exhibits filed include the form of Purchase Agreement (10.1) and the Purchase Agreement with Mr. He (10.2).

14-09-2026

Plains All American Pipeline, L.P. completed a public offering of $1.5 billion in junior subordinated notes, consisting of $700 million of 6.750% Series A Notes and $800 million of 7.000% Series B Notes, both due 2056. The notes are unsecured, subordinated obligations with no subsidiary guarantees, and interest rates are subject to reset in 2031 and 2036, respectively. The offering was underwritten by a syndicate led by J.P. Morgan, Citigroup, Mizuho, MUFG, and Truist.

• · The notes will mature on December 15, 2056.
• · Interest is payable semi-annually on June 15 and December 15, commencing June 15, 2027.
• · Interest rates on Series A Notes reset on December 15, 2031, and on Series B Notes on December 15, 2036, and every five years thereafter, based on the Five-Year U.S. Treasury Rate plus a spread, with a floor at the initial rate.
• · PAA may redeem the notes during the 90-day period prior to the first reset date and thereafter on any interest payment date.
• · The notes are unsecured, subordinated obligations ranking junior to all existing and future senior indebtedness, and are not guaranteed by any subsidiaries.
• · The offering was made under a shelf registration statement on Form S-3 (No. 333-281967) filed on September 6, 2024.

14-09-2026

Yarrow Bioscience, Inc. (formerly VYNE Therapeutics Inc.) entered into an underwriting agreement on September 10, 2026 to issue and sell 5,769,231 shares of common stock at $26.00 per share, with underwriters exercising in full an option for an additional 865,384 shares. The offering is expected to close on September 14, 2026, with net proceeds of approximately $161.8 million. Directors and executive officers are subject to a 60-day lock-up period.

• · The offering was made under a shelf registration statement on Form S-3 (File No. 333-277609), declared effective by the SEC on August 19, 2026.
• · The final prospectus supplement was filed with the SEC on September 11, 2026.
• · The underwriting agreement includes customary representations, warranties, and indemnification provisions.
• · The underwriters' option was exercised in full on September 11, 2026.

14-09-2026

lululemon athletica inc. filed an 8-K on September 14, 2026, disclosing amendments to its Bylaws, effective September 8, 2026, and related director/officer changes. The amended Bylaws update stockholder meeting procedures, including notice requirements for nominations and proposals, and introduce enhanced disclosure obligations for stockholder nominees. No financial results or monetary figures were included in this filing.

• · Bylaws amended through September 8, 2026, with changes to stockholder meeting procedures.
• · Stockholder notice for nominations must be received between 120 and 150 days prior to the anniversary of the prior year's annual meeting, with exceptions for meeting date changes.
• · Proposed nominees must tender an irrevocable resignation effective upon Board acceptance if they fail to receive the required vote.
• · Enhanced disclosure requirements for stockholder nominees include compensation, relationships, and derivative instruments.
• · Special meetings may be called only by the Board chair, CEO, president, or a majority of the Board.
• · Meetings may be held solely by remote communication as permitted by Delaware law.

14-09-2026

XCF Global, Inc. entered into Amendment No. 1 to its Business Combination Agreement with DevvStream Corp. and Southern Energy Renewables Inc., adjusting the consideration shares to 28.75% for Southern and 14.99% for DevvStream, resulting in pro forma ownership of approximately 69.57% for existing XCF shareholders, 20.00% for Southern shareholders, and 10.43% for DevvStream shareholders. The amendment also removes certain closing conditions (minimum Southern capitalization, Company revenue/EBITDA, Nasdaq Sweden listing, HSR Act clearance) and adds a condition requiring a $1,000,000 investment by GL PART SPV I, LLC concurrent with the amendment. Post-closing, EEME and GL commit to fund at least $4,373,000 within three months and use commercially reasonable efforts to fund an additional $50,000,000 within twelve months.

• · The amendment deletes the minimum Southern capitalization condition (Sections 10.2(f) and 10.4(i)).
• · The amendment deletes the Company revenue and EBITDA condition (Section 10.4(h)).
• · The amendment removes the requirement for Nasdaq Sweden listing approval and HSR Act clearance.
• · The Southern Bond Issuance condition is amended to require approval by the State of Louisiana for bonds of at least $400,000,000 aggregate principal amount and a related press conference or release.
• · The post-closing Funding Commitment includes a minimum of $4,373,000 (plus Shortfall Amount) within 3 months and an additional $50,000,000 within 12 months, with EEME and GL jointly responsible.
• · The Shortfall Amount is defined as the amount by which $4,627,000 exceeds certain prior investments by EEME into Southern as detailed in Schedule 5.3(a).

14-09-2026

Avalon GloboCare Corp. (ALBT) entered into a Note Purchase Agreement with Change Agents Corporation and purchasers including C/M Capital Master Fund, LP, issuing pre-funded warrants for up to 100,000 shares at $0.0001 per share. The agreement includes a Most Favored Nation clause, a prohibition on additional debt without majority holder consent, and a Roll-Over Right allowing purchasers to apply outstanding note amounts toward future financings. However, the company is subject to a 19.99% issuance cap under Nasdaq rules unless stockholder approval is obtained, and is prohibited from entering into variable rate transactions until April 2027.

• · The agreement is governed by Delaware law with exclusive jurisdiction in Delaware state courts and the U.S. District Court for the District of Delaware.
• · The company must reserve 100% of the maximum shares issuable upon full exercise of all outstanding Pre-Funded Warrants (without regard to exercise limitations) as the Required Reserve Amount.
• · Any material breach of covenants that remains uncured for 10 Business Days after written notice constitutes an Event of Default.
• · The company is prohibited from entering into Variable Rate Transactions until April 2027 without majority holder consent, with violations constituting an immediate Event of Default.
• · The Pre-Funded Warrants include a beneficial ownership limitation of 4.99% (adjustable up to 9.99% upon 61 days' notice).

14-09-2026

Sionna Therapeutics announced it will advance its dual combination SION-451 + SION-2222 into a Phase 2a proof-of-concept trial in Q1 2027, based on post hoc analyses of the failed SION-719 trial that showed a mean placebo-adjusted sweat chloride reduction of up to -8.6 mmol/L after excluding confounded participants. To prioritize the dual combination and extend cash runway into H2 2029, the company implemented a 46% workforce reduction and other cost-saving measures, expecting aggregate restructuring charges of approximately $6.4 million. While the company ended Q2 2026 with $268.3 million in cash and sees potential in the NBD1 mechanism, the prior trial failed its primary endpoint and key confounding factors were identified, tempering the positive outlook.

• · Post hoc analysis identified three confounding factors in PreciSION CF trial: PK outliers, lowered Trikafta exposures during treatment periods (mean decline of ~25-30%), and CFTR channel biology interactions.
• · Primary analysis in the trial showed placebo-adjusted sweat chloride change of -1.0 mmol/L; secondary analysis showed -1.1 mmol/L.
• · Excluding three PK outlier participants from the secondary analysis resulted in a placebo-adjusted sweat chloride change of -8.6 mmol/L.
• · Phase 1 trial of SION-451-based dual combinations achieved safety, tolerability, and PK objectives; SION-451 + SION-2222 was the preferred combination based on target exposure coverage.
• · AscenSION CF Phase 2a trial will be open-label, 28-day, enrolling adults homozygous for F508del who switch from Trikafta.
• · Cash runway extended into the second half of 2029.

14-09-2026

Magnolia Oil & Gas Corporation (MGY) completed its acquisition of WildFire Energy on September 10, 2026. The deal was previously announced and has now closed, expanding Magnolia's operations in the Eagle Ford Shale and Austin Chalk formations. No financial terms or performance metrics were disclosed in this filing.

• · Acquisition was previously announced and has now closed.
• · Operations are concentrated in South Texas in the core of the Eagle Ford Shale and Austin Chalk formations.
• · Company strategy focuses on moderate annual production growth, high pre-tax operating margins, consistent free cash flow, and strong cash returns to shareholders.

14-09-2026

Elmet Group Co. (NASDAQ: ELMT) announced a $450 million committed investment from the U.S. Department of War to expand domestic tungsten manufacturing and secure critical mineral supply chains. The investment includes an initial $200 million drawdown, redeemable preferred equity, warrants for up to 19.9% of common stock, and a board seat. Separately, ELMT secured an IDIQ contract with the Defense Logistics Agency valued up to $2 billion (with a $150 million guaranteed commitment) to support the National Defense Stockpile. The company plans to invest over $165 million in U.S. facilities and approximately $150 million in a joint venture to restart tungsten processing in Nevada. While the funding and contracts represent significant growth catalysts, the company faces execution risks related to restarting mining operations and expanding capacity, and deliveries to the stockpile will not begin until incremental supply is available, which may delay revenue recognition.

• · The DoW investment includes redeemable preferred equity, warrants for up to 19.9% of common stock, and rights to appoint one independent director and one non-voting board observer.
• · ELMT entered a restricted entity compliance plan with Continental Stock Transfer & Trust to deter Restricted Entities from acquiring 10% or more of outstanding common stock.
• · The IDIQ contract has a five-year base ordering period through August 30, 2031, with a two-year extension option through August 30, 2033.
• · ELMT does not intend to begin delivering material into the National Defense Stockpile until sufficient incremental supply becomes available from mining investments and processing expansions.
• · The company plans to allocate approximately $150 million to Blue Moon's Springer Tungsten Complex in Imlay, Nevada, forming a majority-owned joint venture to restart APT conversion capacity.
• · ELMT is the only U.S.-owned, vertically-integrated producer of tungsten servicing critical end markets.
• · Advisors include Goldman Sachs, Cantor Fitzgerald, Akin Gump, Ellenoff Grossman, and Joele Frank.

14-09-2026

Quince Therapeutics completed the sale of its Italian subsidiary and related assets (including the eDSP/EryDex technology and AIDE systems) to Ayma Therapeutics for $450,000 in cash, with a preliminary pro forma gain on sale of $1.749 million. The transaction eliminates the Italian subsidiary's operating losses, reducing pro forma net loss for the six months ended June 30, 2026 from $41.071 million to $52.447 million (a 28% increase in net loss), reflecting transaction costs and tax impacts. The company also effected 1-for-10 and 1-for-20 reverse stock splits in April 2026, which are reflected in the pro forma figures.

• · The sale transaction closed on September 8, 2026.
• · The company effected a 1-for-10 reverse stock split effective April 10, 2026, and a 1-for-20 reverse stock split (dates not specified).
• · Pro forma adjustments include elimination of Quince SPA's operating results, derecognition of assets and liabilities, and recognition of transaction costs and tax impacts.
• · The pro forma gain on sale is preliminary and could change materially as additional information is obtained.
• · The company elected not to present Management's Adjustments under Article 11 of Regulation S-X.
• · The pro forma financial information is for illustrative purposes only and does not purport to represent actual results.

14-09-2026

I-ON Digital Corp. filed an 8-K on September 14, 2026, disclosing an officer change under Item 5.02. The filing does not specify the position affected, whether it is an appointment or resignation, or the reason for the change. No financial metrics, governance details, or forward-looking statements are provided, making the disclosure minimal and largely informational.

14-09-2026

Firefly Neuroscience, Inc. terminated CFO Paul Krzywicki effective September 24, 2026, and appointed Jessica Paz as Chief Accounting Officer effective September 8, 2026. Ms. Paz will receive an annual base salary of $215,000 and a stock option to purchase 50,000 shares vesting over four years. The termination was not due to any disagreement with the company.

• · Ms. Paz, 46, most recently served as Senior Director of Accounting and Operations at Genvid Holdings, Inc. from April 2020 to August 2026.
• · Ms. Paz holds a Master of Science in Accounting and Finance and an MBA in Technology Management from SUNY Polytechnic Institute, and a BS in Accounting from Hunter College.
• · The Paz Indemnification Agreement provides for advancement of expenses within 20 days of written request, without regard to ultimate entitlement to indemnification.
• · The Employee Confidential Information and Inventions Assignment Agreement includes non-competition provisions during employment and non-solicitation provisions lasting one year post-employment.

14-09-2026

Genasys Inc. entered into a First Amendment to its Loan Agreement with Maran Partners Fund, LP, extending the maturity date to October 30, 2026, and reducing the outstanding principal by $800,000 to $3.5 million. The amendment also modifies prepayment notice requirements and changes governing law to Delaware, while adding a $92,500 amendment fee. No events of default were reported, and the company reaffirmed its representations and warranties.

• · The amendment includes a release by the Borrower of all claims against the Lender, except for fraud, gross negligence, willful misconduct, or bad faith.
• · The amendment waives the right to a trial by jury for any litigation arising from the loan agreement.
• · The amendment adds a definition for 'Amended Whitebox Facility' referencing a separate term loan and security agreement dated May 13, 2024, with multiple amendments.
• · The maturity date was extended to October 30, 2026, from the original date.
• · The governing law was changed to Delaware, with exclusive jurisdiction in Denver, Colorado.

14-09-2026

Health Catalyst announced the appointment of Tami Reller to its board of directors, effective October 1, 2026, where she will serve as audit chair and compensation committee member. The appointment follows the naming of Simeon Kohl as CEO and President, effective September 14, 2026. The company highlights its AI-forward strategy, 18 years of results, and $2.8 billion in validated outcomes, but also discloses risks including client churn, macroeconomic challenges, and the potential underperformance of the Vitalware divestiture.

• · Tami Reller previously served as President (2021-2022), CEO (2022-2023), and Executive Chair (2023-2024) at Duly Health and Care.
• · Reller has been a board member of SPS Commerce since 2016, including five years as board chair.
• · Reller served on Avalara's board from 2014 until its acquisition, including audit and compensation committee roles.
• · Reller held senior executive roles at Microsoft and UnitedHealth Group subsidiaries, including EVP and Chief Marketing and Experience Officer at UnitedHealthcare, and CFO, CMO, and Chief Growth Officer at Optum.
• · Reller served as Treasurer of Seattle Children’s Hospital Foundation and on the board of Fairview Health Services.
• · The company's risk factors include potential client churn or down-selling related to the migration to Ignite.
• · The divestiture of Vitalware may not achieve expected benefits and could adversely affect the business.
• · Forward-looking statements are subject to risks including litigation, security incidents, macroeconomic challenges, and regulatory changes.

14-09-2026

Crown Castle announced the retirement of CFO Sunit Patel (effective March 31, 2027) and the departure of COO Cathy Piche (effective September 23, 2026). Kris Hinson, currently EVP & Chief Commercial Officer, will succeed Patel as CFO on April 1, 2027. The company has initiated a search for Piche's replacement. The leadership changes follow the company's strategic shift back to a pure-play U.S. tower business after divesting its fiber and small cell operations.

• · Sunit Patel will retire effective March 31, 2027, after the filing of the 2026 Form 10-K.
• · Kris Hinson will become CFO on April 1, 2027.
• · Cathy Piche steps down as COO on September 23, 2026, and will serve as a special advisor until February 22, 2027.
• · Kris Hinson holds an MBA from Harvard Business School and an AB in Economics from Harvard College.
• · Kris Hinson previously served as VP-Corporate Finance and Treasurer, and before that spent 13 years at ExxonMobil in finance leadership roles.
• · Cathy Piche currently serves as Chair of the Wireless Infrastructure Association.

14-09-2026

Bimini Capital Management, Inc. announced that Richard Parry has joined its board of directors as a Class II director with a term expiring in 2029. Mr. Parry is President and Chief Investment Officer of Tom Johnson Investment Management, LLC (TJIM), an 80%-owned subsidiary acquired earlier this year. The appointment underscores the company's commitment to growing its asset management business following the TJIM acquisition.

• · Mr. Parry will not receive separate compensation for his board service but may be reimbursed for out-of-pocket expenses related to conferences or educational seminars.
• · Mr. Parry is not expected to serve on any board committee at this time.
• · A trust affiliated with Mr. Parry retains an equity interest in TJIM.

14-09-2026

Envirotech Vehicles, Inc. (now Azio AI Holdings, Inc.) appointed Larry G. Paige II as a Class III independent director effective September 8, 2026, filling an existing vacancy. Mr. Paige will also serve on the Audit, Compensation, and Nominating & Corporate Governance Committees. The filing does not include any financial results or period-over-period comparisons, so no quantitative performance data is available.

• · Mr. Paige's appointment is effective September 8, 2026, with a term expiring at the 2026 annual meeting.
• · He will receive a prorated portion of the annual cash retainer for non-employee directors for the remainder of 2026.
• · Mr. Paige has over 30 years of experience in military logistics, federal contracting, infrastructure, technology, energy resilience, and program execution.
• · He holds multiple advanced degrees including an M.S. in Material Logistics & Operations Research Analysis and an M.S. in Project Management.

14-09-2026

Apogee Enterprises announced the election of Julie K. Streich as an independent director and her appointment to the Audit Committee, effective September 11, 2026. Ms. Streich brings extensive public-company board, financial, and operational experience, including her current role as Audit Committee Chair of Schneider National and prior service as CFO of Barnes Group. The appointment is a routine board refreshment and does not involve any financial results or material operational changes.

• · Ms. Streich served as CFO of Barnes Group from 2021 until retirement in March 2026, and as Interim CEO from March 2022 to July 2022.
• · She holds a BA in Economics and Spanish from Ripon College and an MBA in International Business from the University of Texas at San Antonio.
• · She has served on the board of Schneider National since 2023 and chairs its Audit Committee.

14-09-2026

Bowhead Specialty Holdings Inc. elected Derek Walker to its Board of Directors on September 12, 2026, filling a vacancy recommended by GPC Partners Investments (SPV III) LP. Mr. Walker, a Managing Director at Gallatin Point Capital LLC, brings extensive investment and management experience and will serve as a Class II director until the 2032 annual meeting. He will not receive any cash fees or compensation for his Board service.

• · Mr. Walker was recommended by GPC Fund under the Board Nominee Agreement dated May 23, 2024.
• · Mr. Walker will stand for reelection at the 2029 annual meeting as a Class II director with term expiring at the 2032 annual meeting.
• · Mr. Walker is not eligible to receive any cash fees or other compensation for his Board service.
• · Mr. Walker holds a B.A. (magna cum laude, phi beta kappa) in Economics from Yale University and an M.B.A. (Arjay Miller Scholar) from Stanford University Graduate School of Business.

14-09-2026

CitroTech (NYSE American: CITR), formerly General Enterprise Ventures (GEVI), presented its commercial-phase strategy for its citric-acid-derived wildfire prevention platform. The company highlighted a 50/50 HexiTech JV with Hexion, a 20+ partner channel expansion, and expects USFS QPL qualification for ground-based retardants during the 2027 fire season. However, the filing also discloses a going concern warning, noting substantial doubt about the company's ability to continue as a going concern for one year, and that CitroTech products are not currently on any USFS Qualified Products List.

• · CitroTech products are not currently listed on any U.S. Forest Service Qualified Products List.
• · EPA Safer Choice recognition is not a U.S. Forest Service qualification, an efficacy endorsement, or an approval for use on federal lands.
• · Management has concluded that conditions exist that raise substantial doubt about the company's ability to continue as a going concern for one year.
• · From year five, Hexion may acquire CitroTech's 50% JV interest at a valuation reflecting what the JV has become.
• · The company has 31 issued and 56 pending patents.
• · CitroTech is targeting ground-based QPL approval initially, not aerial.
• · The company's market cap figures are approximate and presented for reference only.

14-09-2026

AIM ImmunoTech Inc. entered into exchange agreements with Streeterville Capital, LLC to convert approximately $400,000 of a promissory note into 1,749,434 shares of common stock at an average conversion price of $0.228 per share. The conversion was approved by stockholders in July 2026 and was conducted under an exemption from SEC registration. This debt-to-equity conversion reduces the company's debt but significantly dilutes existing shareholders.

• · The exchange agreements were entered into between September 8 and September 9, 2026.
• · The conversion price of approximately $0.228 per share represents a significant discount to the stock's likely market price, indicating potential dilution for existing shareholders.
• · The shares were issued under Section 3(a)(9) of the Securities Act, which exempts securities exchanged with an existing security holder without any commission or solicitation.

14-09-2026

Dexcom announced the promotion of Jereme Sylvain to Chief Operating Officer (COO), in addition to his existing role as Chief Financial Officer (CFO). Mr. Sylvain will now oversee global operations and quality teams, aiming to improve alignment and operational efficiency. The move reflects internal succession planning and a focus on scaling the business, but no financial metrics or performance data were disclosed in this filing.

• · Jereme Sylvain joined Dexcom in 2018 and has served as EVP and CFO since 2021.
• · The promotion is effective as of September 14, 2026.
• · No financial figures, revenue, or profit metrics were provided in the filing.

14-09-2026

Upexi, Inc. amended its BitGo Prime credit facility, reducing the interest rate from 11.5% to 7.5% per year and lowering the required collateral to 200% with a margin call level of 150%. The company expects to save over $2 million in annual interest costs based on current borrowings, reflecting continued cost-reduction and balance-sheet strengthening efforts. No negative or flat metrics were reported in this filing.

• · The credit facility was originally entered into on May 23, 2025 under a Master Loan Agreement.
• · Upexi currently holds over two million SOL.
• · The company operates as a Solana-focused digital asset treasury company and also owns consumer brands.
• · The amendment reduces the interest rate by four percentage points (from 11.5% to 7.5%).

14-09-2026

CIMG Inc. announced the resignation of director Changzheng Ye for personal reasons, effective September 8, 2026, with no disagreement with the company. The board appointed Dongwei Li as an independent director and Audit Committee Chair, effective September 11, 2026, to fill the vacancy. Mr. Li will receive annual cash compensation of $25,000.

• · Mr. Li, 35, is Co-Founder of Zeen Tendering and Procurement (Guangdong) Co., Ltd. since January 2021.
• · From January 2015 to December 2020, Mr. Li was Director of Major Projects at Shenzhen Pagoda Industrial (Group) Corporation Limited.
• · Mr. Li holds a Bachelor of Science in Computer Science and Technology from Zhengzhou University (2009).
• · The company entered into a director offer letter and an indemnification agreement with Mr. Li, each dated September 11, 2026.

14-09-2026

Z Squared Inc. (Nasdaq: ZSQR) announced the closing of its acquisition of Paradox Data, LLC, acquiring the energized Union County Campus in El Dorado, Arkansas, as its first owned AI-ready colocation site. The campus currently has 8.0 MW of interruptible power from Entergy Arkansas, with a development target of 150+ MW through phased conversion and adjacent land acquisition; the acquisition was completed entirely in stock with no cash or debt. While the company achieved its first goal of closing the deal, the expanded capacity remains a development target with no signed customer commitments yet, and the company must still secure power arrangements, financing, and permits.

• · The campus electric service is interruptible (not guaranteed) under the Entergy Arkansas arrangement.
• · Expansion beyond 8.0 MW depends on additional power arrangements, customer commitments, financing, permitting, and construction.
• · The company intends to acquire additional sites without taking on debt, but this is subject to discipline and not guaranteed.
• · Z Squared's common stock began trading on Nasdaq under symbol 'ZSQR' in April 2026.

14-09-2026

Addus HomeCare Corp announced a definitive agreement to acquire the personal care division of AccentCare for approximately $275.0 million, expected to add about $280 million in annualized revenue (a roughly 19% increase to Addus' revenue base) and be accretive to financial results. The acquisition expands Addus' personal care operations into 10 states, including Texas, Illinois, California, and Arizona, and is expected to close following regulatory approvals. The transaction is funded through a combination of Addus' revolver and cash on hand.

• · Acquired operations serve an average daily census of approximately 13,700 customers through locations in a 10-state footprint.
• · Acquisition does not include AccentCare's personal care operations in New York, nor its hospice and home health operations.
• · Addus currently provides home care services to approximately 62,500 consumers through 264 locations across 24 states.
• · AccentCare currently cares for over 200,000 patients and clients annually in more than 280 locations across 30 states and the District of Columbia.
• · Evercore is financial advisor and Bass Berry & Sims PLC is legal counsel to Addus; Guggenheim Securities, LLC and J.P. Morgan are financial advisors and Ropes & Gray, LLP is legal counsel to AccentCare.